The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The partnership initially will focus on cardiovascular and kidney diseases
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Subscribe To Our Newsletter & Stay Updated
